Sanofi ADR is a drug manufacturers - general business based in the US. Sanofi ADR shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Sanofi ADR employs 86,088 staff and has a trailing 12-month revenue of around $46.3 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $53.10 |
|---|---|
| 52-week range | $42.63 - $55.72 |
| 50-day moving average | $49.19 |
| 200-day moving average | $48.68 |
| Wall St. target price | $59.89 |
| PE ratio | 28.9231 |
| Dividend yield | $0 (3.98%) |
| Earnings per share (TTM) | $1.82 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $53.1 from 2024-07-25
| 1 week (2024-07-19) | 4.90% |
|---|---|
| 1 month (2024-06-26) | 9.87% |
| 3 months (2024-04-26) | 8.08% |
| 6 months (2024-01-26) | 5.90% |
| 1 year (2023-07-26) | -0.77% |
|---|---|
| 2 years (2022-07-26) | 5.46% |
| 3 years (2021-07-26) | 2.85% |
| 5 years (2019-07-26) | 34.92% |
Valuing Sanofi ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Sanofi ADR shares trade at around 29x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Sanofi ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8375. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sanofi ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.2 billion.
The EBITDA is a measure of a Sanofi ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $46.3 billion |
|---|---|
| Operating margin TTM | 18.28% |
| Gross profit TTM | $31.7 billion |
| Return on assets TTM | 4.54% |
| Return on equity TTM | 7.27% |
| Profit margin | 9.8% |
| Book value | $59.17 |
| Market Capitalization | $131.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 31.29% of net profits
Recently Sanofi ADR has paid out, on average, around 31.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.98% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi ADR shareholders could enjoy a 3.98% return on their shares, in the form of dividend payments. In Sanofi ADR's case, that would currently equate to about $0 per share.
While Sanofi ADR's payout ratio might seem fairly standard, it's worth remembering that Sanofi ADR may be investing much of the rest of its net profits in future growth.
Sanofi ADR's most recent dividend payout was on 5 June 2024. The latest dividend was paid out to all shareholders who bought their shares by 8 May 2024 (the "ex-dividend date").
Sanofi ADR's shares were split on a 5:1 basis on 29 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi ADR shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi ADR shares which in turn could have impacted Sanofi ADR's share price.
Over the last 12 months, Sanofi ADR's shares have ranged in value from as little as $42.63 up to $55.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi ADR's is 0.408. This would suggest that Sanofi ADR's shares are less volatile than average (for this exchange).
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.